Pharmacotherapy of major depressive disorder

U.S. Pharmacist

Volumn 36, Issue 11, 2011, Pages

  Brown, Charles H ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; HALLUCINATION; HUMAN; MAJOR DEPRESSION; PREVALENCE; SOCIAL STATUS; WESTERN HEMISPHERE; WORLD HEALTH ORGANIZATION;

EID: 81355135878     PISSN: 01484818     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (68)

1. Barlow DH. Abnormal Psychology: An Integrative Approach. 5th ed. Belmont, CA: Thomson Wadsworth; 2005:248-249.
2. Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey replication. Arch Gen Psychiatry. 2005;62:617-627.
3. The World Health Organization. Annex Table 3: Burden of disease in DALYs by cause, sex, and mortality stratum in WHO regions, estimates for 2002. In: The World Health Report 2004: Changing History. Geneva, Switzerland: WHO; 2004.
4. Major depressive disorder. American Medical Network, Inc. www.health.am/psy/major- depressive-disorder/. Accessed October 5, 2011.
5. Kessler RC, Berglund P, Demler O, et al; National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095-3105.
6. Depression in boys and adolescent males. National Institute of Mental Health. www.nimh.nih.gov/health/ publications/men-and- depression/depression-in-boys- and-adolescent-males.shtml. Accessed October 5, 2011.
7. National Institute of Mental Health. Depression. NIH Pub. No. 11-3561. Revised 2011. www.nimh.nih.gov/health/ publications/depression/ depression-booklet-pdf.pdf. Accessed October 5, 2011.
8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Publishing; 2000.
9. Delgado PL, Schillerstrom J. Cognitive difficulties associated with depression: what are the implications for treatment? Psychiatr Times. 2009;26(3).
10. Faculty of Psychiatry of Old Age, NSW Branch, RANZCP. Consensus Guidelines for Assessment and Management of Depression in the Elderly. North Sydney, New South Wales: NSW Health Department; 2001.
11. Yohannes AM, Baldwin RC. Medical comorbidities in late-life depression. Psychiatric Times. 2008;25:52-55.
12. McCullough ME, Larson DB. Religion and depression: a review of the literature. Twin Res. 1999;2:126-136.
13. Dein S. Religion, spirituality and depression: implications for research and treatment. Prim Care Community Psychiatr. 2006;11:67-72.
14. Moreira-Almeida A, Neto FL, Koenig HG. Religiousness and mental health: a review. Rev Bras Psiquiatr. 2006;28:242-250.
15. Tsuang MT, Faraone SV. The Genetics of Mood Disorders. Baltimore, MD: Johns Hopkins University Press; 1990.
16. Lewinsohn PM, Hoberman HH, Rosenbaum M. A prospective study of risk factors for unipolar depression. J Abnorm Psychol. 1988;97:251-264.
17. U.S. Department of Health and Human Services (HHS). The Fundamentals of Mental Health and Mental Illness. Rockville, MD: HHS; 1999.
18. Biological causes of depression. All About Depression. www.allaboutdepression.com/ cau_02.html. Accessed October 5, 2011.
19. Barlow DH. Abnormal Psychology: An Integrative Approach. 5th ed. Belmont, CA: Thomson Wadsworth; 2005:226.
20. Shah N, Eisner T, Farrell M, Raeder C. An overview of SSRIs for the treatment of depression. J Pharm Soc Wisc. 1999;July/August:33-49.
21. Nutt DJ. Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psychiatry. 2008;69(suppl E1):4-7.
22. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature. 2008;455:894-902.
23. Hirschfeld RM. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry. 2000;61(suppl 6):4-6.
24. World Health Organization (WHO) Family of International Classifications. Chapter V. Mental and behavioural disorders (F00-F99). Mood [affective] disorders (F30-F39). http://apps.who.int/ classifications/apps/icd/ icd10online2005/fr-icd.htm? gf30.htm. Accessed October 5, 2011.
25. WHO. The ICD-10 Classification of Mental and Behavioral Disorders. Clinical Description and Diagnostic Guideline. Geneva, Switzerland: WHO; 1992.
26. Orengo C, Fullerton G, Tan R. Male depression: a review of gender concerns and testosterone therapy. Geriatrics. 2004;59:24-30.
27. Gaynes BN, Rush AJ, Trivedi MH, et al. The STAR*D study: treating depression in the real world. Cleve Clin J Med. 2008;75:57-66.
28. Depression Guideline Panel. Clinical practice guideline, number 5. Depression in Primary Care: Volume 1. Detection and Diagnosis. AHCPR Pub. No. 93-0551. Rockville, MD: HHS, Agency for Health Care Policy and Research; 1993.
29. American Psychiatric Association. Practice Guideline For The Treatment of Patients With Major Depressive Disorder, Third Edition. November 2010. www.psychiatryonline.com/ pracGuide/pracGuideTopic_7.aspx. Accessed October 5, 2011.
30. Miller AL, Hall CS, Buchanan RW, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry. 2004;65:500-508.
31. Nemeroff CB. Improving antidepressant adherence. J Clin Psychiatry. 2003;64:25-30.
32. Thase ME. Preventing relapse and recurrence of depression: a brief review of therapeutic options. CNS Spectr. 2006;11(suppl 15):12-21.
33. Antidepressant use in children, adolescents, and adults. FDA. May 2, 2007. www.fda.gov/Drugs/DrugSafety/ InformationbyDrugClass/ UCM096273. Accessed October 5, 2011.
34. Whooley MA, Simon GE. Managing depression in medical outpatients. N Engl J Med. 2000;343:1942-1950.
35. Zisook S, Rush AJ, Haight BR, et al. Use of bupropion in combination with serotonin reuptake inhibitors. Biol Psychiatry. 2006;59:203-210.
36. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354:1231-1242.
37. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354:1243-1252.
38. Papakostas GI, Thase ME, Fava M, et al. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry. 2007;62:1217-1227.
39. National Institute for Health and Clinical Excellence. Depression in Children and Young People: Identification and Management in Primary, Community and Secondary Care. Leicester, UK: British Psychological Society; 2005.
40. Lexapro (escitalopram oxalate) package insert. St. Louis, MO: Forest Laboratories; May 2011.
41. Mayers AG, Baldwin DS. Antidepressants and their effect on sleep. Hum Psychopharmacol. 2005;20:533-559.
42. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352:1112-1120.
43. Viibryd (vilazodone) package insert. St. Louis, MO: Forest Laboratories; March 2011.
44. Effexor XR (venlafaxine) package insert. Philadelphia, PA: Wyeth Pharmaceuticals Inc; July 2009.
45. Cymbalta (duloxetine) package insert. Indianapolis, IN: Eli Lilly and Company; September 2011.
46. Pristiq (desvenlafaxine) package insert. Philadelphia, PA: Wyeth Pharmaceuticals Inc; July 2011.
47. Cooper AJ. Tyramine and irreversible monoamine oxidase inhibitors in clinical practice. Br J Psychiatry Suppl. 1989;(6):38-45.
48. Mallinger AG, Smith E. Pharmacokinetics of monoamine oxidase inhibitors. Psychopharmacol Bull. 1991;27:493-502.
49. Fiedorowicz JG, Swartz KL. The role of monoamine oxidase inhibitors in current psychiatric practice. J Psychiatr Pract. 2004;10:239-248.
50. Horwitz D, Lovenberg W, Engelman K, Sjoerdsma A. Monoamine oxidase inhibitors, tyramine, and cheese. JAMA. 1964;188:1108-1110.
51. Gardner DM, Shulman KI, Walker SE, Tailor SA. The making of a user friendly MAOI diet. J Clin Psychiatry. 1996;57:99-104.
52. Shulman KI, Walker SE. Refining the MAOI diet: tyramine content of pizza and soy products. J Clin Psychiatry. 1999;60:191-193.
53. Patkar AA, Pae CU, Masand PS. Transdermal selegiline: the new generation of monoamine oxidase inhibitors. CNS Spectr. 2006;11:363-375.
54. Lorenz RA, Vandenberg AM, Canepa EA. Serotonergic antidepressants and linezolid: a retrospective chart review and presentation of cases. Int J Psychiatry Med. 2008;38:81-90.
55. Miller DG, Lovell EO. Antibiotic-induced serotonin syndrome. J Emerg Med. 2011;40:20-27.
56. Das PK, Warkentin DI, Hewko R, Forrest DL. Serotonin syndrome after concomitant treatment with linezolid and meperidine. Clin Infect Dis. 2008;46:264-265.
57. Packer S, Berman SA. Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid. Am J Psychiatry. 2007;164:346-347.
58. Marangell LB. Switching antidepressants for treatment-resistant major depression. J Clin Psychiatry. 2001;62(suppl 18):12-17.
59. Evans DL, Davidson J, Raft D. Early and late side effects of phenelzine. J Clin Psychopharmacol. 1982;2:208-210.
60. Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacology. 2007;151:737-748.
61. Teicher MH, Glod CA, Cole JO. Antidepressant drugs and the emergence of suicidal tendencies. Drug Saf. 1993;8:186-212.
62. Gorman JM. Mirtazapine: clinical overview. J Clin Psychiatry. 1999;60(suppl 17):9-13.
63. Terry P, Katz JL. Dopaminergic mediation of the discriminative stimulus effects of bupropion. Psychopharmacology. 1997;134:201-212.
64. Learned-Coughlin SM, Bergstrom M, Savitcheva I, et al. In vivo activity of bupropion at the human dopamine transporter. Biol Psychiatry. 2003;54:800-805.
65. Symbyax (olanzapine and fluoxetine hydrochloride) package insert. Indianapolis, IN: Eli Lilly & Co; August 2011.
66. Seroquel XR (quetiapine fumarate) package insert. Wilmington, DE: AstraZeneca Pharmaceuticals LP; July 2011.
67. Abilify (aripiprazole) package insert. Tokyo, Japan: Otsuka Pharmaceutical Company; February 2011.
68. Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St. John's wort) in major depressive disorder: a randomized, controlled trial. JAMA. 2002;287:1807-1814.